Free Newsletter
N.C. town welcomes Novartis plant
Tomorrow's grand opening of a Novartis flu vaccine plant in North Carolina illustrates just how important pharma facilities can be to local economies--and just how far governments will go to attract them. Bearing in mind that plants and research labs alike are shutting down across the U.S. because of mega-mergers, it's instructive to remind ourselves that the very same facilities once inspired such hope.
And such tax breaks. Now, we're not suggesting that Novartis will end up shutting down this brand-spanking-new vaccine plant. But we don't mind telling you that Holly Springs, the plant's new home, borrowed $8.3 million to buy the company 167 acres of land. Or that the town spent $12 million on roads and other infrastructure. The state of North Carolina added more incentives, bringing the total incentive package to more than $40 million, the News & Observer reports.
Considering that Novartis has since added $225 million to the town's tax base, the perks could be worth it. As the N&O points out, the town was among the few in the area to increase its budget this fiscal year. And the drugmaker's presence has already attracted more business to the area, the paper reports. For North Carolina and Holly Springs' sake, let's hope the upward trend continues.
- read the story in the N&O
Related Articles:
HHS, Novartis ink $486M vaccine deal
Novartis to build $600M flu plant in N.C.
Comments
The investments by Holly Springs and by the State may also attract more and better graduate students in molecular biology to the state's graduate schools. After they get their PhD degrees, they will be more inclined to remain in North Carolina if the state has a strong research and manufaturing base in biomedicine. If they start families in North Carolina this benefits school systems. Better school systems encourage other businesses to bring their enterprises to the state.
Is it a gamble? Of course it is, but Holly Springs and North Carolina must like the odds. What state would NOT mind having a facility like this, rather than, for example, a new automobile manufacturing plant?
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





